Co-ordinated multidisciplinary intervention to reduce time to successful extubation for children on mechanical ventilation: the SANDWICH cluster stepped-wedge RCT

BACKGROUND: Daily assessment of patient readiness for liberation from invasive mechanical ventilation can reduce the duration of ventilation. However, there is uncertainty about the effectiveness of this in a paediatric population. OBJECTIVES: To determine the effect of a ventilation liberation intervention in critically ill children who are anticipated to have a prolonged duration of mechanical ventilation (primary objective) and in all children (secondary objective). DESIGN: A pragmatic, stepped-wedge, cluster randomised trial with economic and process evaluations. SETTING: Paediatric intensive care units in the UK. PARTICIPANTS: Invasively mechanically ventilated children (aged < 16 years). INTERVENTIONS: The intervention incorporated co-ordinated multidisciplinary care, patient-relevant sedation plans linked to sedation assessment, assessment of ventilation parameters with a higher than usual trigger for undertaking an extubation readiness test and a spontaneous breathing trial on low levels of respiratory support to test extubation readiness. The comparator was usual care. Hospital sites were randomised sequentially to transition from control to intervention and were non-blinded. MAIN OUTCOME MEASURES: The primary outcome measure was the duration of invasive mechanical ventilation until the first successful extubation. The secondary outcome measures were successful extubation, unplanned extubation and reintubation, post-extubation use of non-invasive ventilation, tracheostomy, post-extubation stridor, adverse events, length of intensive care and hospital stay, mortality and cost per respiratory complication avoided at 28 days. RESULTS: The trial included 10,495 patient admissions from 18 paediatric intensive care units from 5 February 2018 to 14 October 2019. In children with anticipated prolonged ventilation (n = 8843 admissions: control, n = 4155; intervention, n = 4688), the intervention resulted in a significantly shorter time to successful extubation [cluster and time-adjusted median difference -6.1 hours (interquartile range -8.2 to -5.3 hours); adjusted hazard ratio 1.11, 95% confidence interval 1.02 to 1.20; p = 0.02] and a higher incidence of successful extubation (adjusted relative risk 1.01, 95% confidence interval 1.00 to 1.02; p = 0.03) and unplanned extubation (adjusted relative risk 1.62, 95% confidence interval 1.05 to 2.51; p = 0.03), but not reintubation (adjusted relative risk 1.10, 95% confidence interval 0.89 to 1.36; p = 0.38). In the intervention period, the use of post-extubation non-invasive ventilation was significantly higher (adjusted relative risk 1.22, 95% confidence interval 1.01 to 1.49; p = 0.04), with no evidence of a difference in intensive care length of stay or other harms, but hospital length of stay was longer (adjusted hazard ratio 0.89, 95% confidence interval 0.81 to 0.97; p = 0.01). Findings for all children were broadly similar. The control period was associated with lower, but not statistically significantly lower, total costs (cost difference, mean £929.05, 95% confidence interval -£516.54 to £2374.64) and significantly fewer respiratory complications avoided (mean difference -0.10, 95% confidence interval -0.16 to -0.03). LIMITATIONS: The unblinded intervention assignment may have resulted in performance or detection bias. It was not possible to determine which components were primarily responsible for the observed effect. Treatment effect in a more homogeneous group remains to be determined. CONCLUSIONS: The intervention resulted in a statistically significant small reduction in time to first successful extubation; thus, the clinical importance of the effect size is uncertain. FUTURE WORK: Future work should explore intervention sustainability and effects of the intervention in other paediatric populations

Atrial Fibrosis Hampers Non-invasive Localization of Atrial Ectopic Foci From Multi-Electrode Signals: A 3D Simulation Study

[EN] Introduction: Focal atrial tachycardia is commonly treated by radio frequency ablation with an acceptable long-term success. Although the location of ectopic foci tends to appear in specific hot-spots, they can be located virtually in any atrial region. Multi-electrode surface ECG systems allow acquiring dense body surface potential maps (BSPM) for non-invasive therapy planning of cardiac arrhythmia. However, the activation of the atria could be affected by fibrosis and therefore biomarkers based on BSPM need to take these effects into account. We aim to analyze the effect of fibrosis on a BSPM derived index, and its potential application to predict the location of ectopic foci in the atria. Methodology: We have developed a 3D atrial model that includes 5 distributions of patchy fibrosis in the left atrium at 5 different stages. Each stage corresponds to a different amount of fibrosis that ranges from 2 to 40%. The 25 resulting 3D models were used for simulation of Focal Atrial Tachycardia (FAT), triggered from 19 different locations described in clinical studies. BSPM were obtained for all simulations, and the body surface potential integral maps (BSPiM) were calculated to describe atrial activations. A machine learning (ML) pipeline using a supervised learning model and support vector machine was developed to learn the BSPM patterns of each of the 475 activation sequences and relate them to the origin of the FAT source. Results: Activation maps for stages with more than 15% of fibrosis were greatly affected, producing conduction blocks and delays in propagation. BSPiMs did not always cluster into non-overlapped groups since BSPiMs were highly altered by the conduction blocks. From stage 3 (15% fibrosis) the BSPiMs showed differences for ectopic beats placed around the area of the pulmonary veins. Classification results were mostly above 84% for all the configurations studied when a large enough number of electrodes were used to map the torso. However, the presence of fibrosis increases the area of the ectopic focus location and therefore decreases the utility for the electrophysiologist. Conclusions: The results indicate that the proposed ML pipeline is a promising methodology for non-invasive ectopic foci localization from BSPM signal even when fibrosis is present.This work was partially supported by Ministerio de Economia y Competitividad and Fondo Europeo de Desarrollo Regional (FEDER) DPI2015-69125-R and TIN2014-59932-JIN (MINECO/FEDER, UE).Godoy, EJ.; Lozano, M.; García-Fernández, I.; Ferrer-Albero, A.; Macleod, R.; Saiz, J.; Sebastián, R. (2018). Atrial Fibrosis Hampers Non-invasive Localization of Atrial Ectopic Foci From Multi-Electrode Signals: A 3D Simulation Study. Frontiers in Physiology. 9:1-18. https://doi.org/10.3389/fphys.2018.00404S1189Boyle, P. M., Zahid, S., & Trayanova, N. A. (2016). Towards personalized computational modelling of the fibrotic substrate for atrial arrhythmia. EP Europace, 18(suppl_4), iv136-iv145. doi:10.1093/europace/euw358Courtemanche, M., Ramirez, R. J., & Nattel, S. (1998). Ionic mechanisms underlying human atrial action potential properties: insights from a mathematical model. American Journal of Physiology-Heart and Circulatory Physiology, 275(1), H301-H321. doi:10.1152/ajpheart.1998.275.1.h301Daccarett, M., Badger, T. J., Akoum, N., Burgon, N. S., Mahnkopf, C., Vergara, G., … Marrouche, N. F. (2011). Association of Left Atrial Fibrosis Detected by Delayed-Enhancement Magnetic Resonance Imaging and the Risk of Stroke in Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 57(7), 831-838. doi:10.1016/j.jacc.2010.09.049Dössel, O., Krueger, M. W., Weber, F. M., Wilhelms, M., & Seemann, G. (2012). Computational modeling of the human atrial anatomy and electrophysiology. Medical & Biological Engineering & Computing, 50(8), 773-799. doi:10.1007/s11517-012-0924-6Ferrer, A., Sebastián, R., Sánchez-Quintana, D., Rodríguez, J. F., Godoy, E. J., Martínez, L., & Saiz, J. (2015). Detailed Anatomical and Electrophysiological Models of Human Atria and Torso for the Simulation of Atrial Activation. PLOS ONE, 10(11), e0141573. doi:10.1371/journal.pone.0141573Ferrer-Albero, A., Godoy, E. J., Lozano, M., Martínez-Mateu, L., Atienza, F., Saiz, J., & Sebastian, R. (2017). Non-invasive localization of atrial ectopic beats by using simulated body surface P-wave integral maps. PLOS ONE, 12(7), e0181263. doi:10.1371/journal.pone.0181263Geselowitz, D. B., & Miller, W. T. (1983). A bidomain model for anisotropic cardiac muscle. Annals of Biomedical Engineering, 11(3-4), 191-206. doi:10.1007/bf02363286Giffard-Roisin, S., Jackson, T., Fovargue, L., Lee, J., Delingette, H., Razavi, R., … Sermesant, M. (2017). Noninvasive Personalization of a Cardiac Electrophysiology Model From Body Surface Potential Mapping. IEEE Transactions on Biomedical Engineering, 64(9), 2206-2218. doi:10.1109/tbme.2016.2629849Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., & Singer, D. E. (2001). Prevalence of Diagnosed Atrial Fibrillation in Adults. JAMA, 285(18), 2370. doi:10.1001/jama.285.18.2370Guillem, M. S., Climent, A. M., Rodrigo, M., Fernández-Avilés, F., Atienza, F., & Berenfeld, O. (2016). Presence and stability of rotors in atrial fibrillation: evidence and therapeutic implications. Cardiovascular Research, 109(4), 480-492. doi:10.1093/cvr/cvw011Heidenreich, E. A., Ferrero, J. M., Doblaré, M., & Rodríguez, J. F. (2010). Adaptive Macro Finite Elements for the Numerical Solution of Monodomain Equations in Cardiac Electrophysiology. Annals of Biomedical Engineering, 38(7), 2331-2345. doi:10.1007/s10439-010-9997-2HOFFMANN, E., REITHMANN, C., NIMMERMANN, P., ELSER, F., DORWARTH, U., REMP, T., & STEINBECK, G. (2002). Clinical Experience with Electroanatomic Mapping of Ectopic Atrial Tachycardia. Pacing and Clinical Electrophysiology, 25(1), 49-56. doi:10.1046/j.1460-9592.2002.00049.xJacquemet, V. (2012). An eikonal-diffusion solver and its application to the interpolation and the simulation of reentrant cardiac activations. Computer Methods and Programs in Biomedicine, 108(2), 548-558. doi:10.1016/j.cmpb.2011.05.003Jalife, J. (2010). Deja vu in the theories of atrial fibrillation dynamics. Cardiovascular Research, 89(4), 766-775. doi:10.1093/cvr/cvq364Keller, D. U. J., Weber, F. M., Seemann, G., & Dössel, O. (2010). Ranking the Influence of Tissue Conductivities on Forward-Calculated ECGs. IEEE Transactions on Biomedical Engineering, 57(7), 1568-1576. doi:10.1109/tbme.2010.2046485Kistler, P. M., Fynn, S. P., Haqqani, H., Stevenson, I. H., Vohra, J. K., Morton, J. B., … Kalman, J. M. (2005). Focal Atrial Tachycardia From the Ostium of the Coronary Sinus. Journal of the American College of Cardiology, 45(9), 1488-1493. doi:10.1016/j.jacc.2005.01.042Kistler, P. M., Roberts-Thomson, K. C., Haqqani, H. M., Fynn, S. P., Singarayar, S., Vohra, J. K., … Kalman, J. M. (2006). P-Wave Morphology in Focal Atrial Tachycardia. Journal of the American College of Cardiology, 48(5), 1010-1017. doi:10.1016/j.jacc.2006.03.058Kistler, P. M., Sanders, P., Fynn, S. P., Stevenson, I. H., Hussin, A., Vohra, J. K., … Kalman, J. M. (2003). Electrophysiological and Electrocardiographic Characteristics of Focal Atrial Tachycardia Originating From the Pulmonary Veins. Circulation, 108(16), 1968-1975. doi:10.1161/01.cir.0000095269.36984.75Kistler, P. M., Sanders, P., Hussin, A., Morton, J. B., Vohra, J. K., Sparks, P. B., & Kalman, J. M. (2003). Focal atrial tachycardia arising from the mitral annulus. Journal of the American College of Cardiology, 41(12), 2212-2219. doi:10.1016/s0735-1097(03)00484-4Andrew MacCannell, K., Bazzazi, H., Chilton, L., Shibukawa, Y., Clark, R. B., & Giles, W. R. (2007). A Mathematical Model of Electrotonic Interactions between Ventricular Myocytes and Fibroblasts. Biophysical Journal, 92(11), 4121-4132. doi:10.1529/biophysj.106.101410MacLeod, R. S., Kholmovski, E., DiBella, E. V. R., Oakes, R. S., Blauer, J. E., Fish, E., … Marrouche, N. F. (2008). Integration of MRI in evaluation and ablation of atrial fibrillation. 2008 Computers in Cardiology. doi:10.1109/cic.2008.4748981Maleckar, M. M., Greenstein, J. L., Giles, W. R., & Trayanova, N. A. (2009). Electrotonic Coupling between Human Atrial Myocytes and Fibroblasts Alters Myocyte Excitability and Repolarization. Biophysical Journal, 97(8), 2179-2190. doi:10.1016/j.bpj.2009.07.054Morgan, R., Colman, M. A., Chubb, H., Seemann, G., & Aslanidi, O. V. (2016). Slow Conduction in the Border Zones of Patchy Fibrosis Stabilizes the Drivers for Atrial Fibrillation: Insights from Multi-Scale Human Atrial Modeling. Frontiers in Physiology, 7. doi:10.3389/fphys.2016.00474MORTON, J. B., SANDERS, P., DAS, A., VOHRA, J. K., SPARKS, P. B., & KALMAN, J. M. (2001). Focal Atrial Tachycardia Arising from the Tricuspid Annulus: Electrophysiologic and Electrocardiographic Characteristics. Journal of Cardiovascular Electrophysiology, 12(6), 653-659. doi:10.1046/j.1540-8167.2001.00653.xNiederer, S. A., Kerfoot, E., Benson, A. P., Bernabeu, M. O., Bernus, O., Bradley, C., … Smith, N. P. (2011). Verification of cardiac tissue electrophysiology simulators using an N -version benchmark. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 369(1954), 4331-4351. doi:10.1098/rsta.2011.0139Oakes, R. S., Badger, T. J., Kholmovski, E. G., Akoum, N., Burgon, N. S., Fish, E. N., … Marrouche, N. F. (2009). Detection and Quantification of Left Atrial Structural Remodeling With Delayed-Enhancement Magnetic Resonance Imaging in Patients With Atrial Fibrillation. Circulation, 119(13), 1758-1767. doi:10.1161/circulationaha.108.811877Ramanathan, C., Jia, P., Ghanem, R., Calvetti, D., & Rudy, Y. (2003). Noninvasive Electrocardiographic Imaging (ECGI): Application of the Generalized Minimal Residual (GMRes) Method. Annals of Biomedical Engineering, 31(8), 981-994. doi:10.1114/1.1588655Santangeli, P., & Marchlinski, F. E. (2017). Techniques for the provocation, localization, and ablation of non–pulmonary vein triggers for atrial fibrillation. Heart Rhythm, 14(7), 1087-1096. doi:10.1016/j.hrthm.2017.02.030Santangeli, P., Zado, E. S., Hutchinson, M. D., Riley, M. P., Lin, D., Frankel, D. S., … Marchlinski, F. E. (2016). Prevalence and distribution of focal triggers in persistent and long-standing persistent atrial fibrillation. Heart Rhythm, 13(2), 374-382. doi:10.1016/j.hrthm.2015.10.023Saoudi, N. (2001). A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases. A Statement from a Joint Expert Group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. European Heart Journal, 22(14), 1162-1182. doi:10.1053/euhj.2001.2658Shah, A. J., Hocini, M., Pascale, P., Roten, L., Komatsu, Y., … Daly, M. (2013). Body Surface Electrocardiographic Mapping for Non-invasive Identification of Arrhythmic Sources. Arrhythmia & Electrophysiology Review, 2(1), 16. doi:10.15420/aer.2013.2.1.16SippensGroenewegen, A., Natale, A., Marrouche, N. F., Bash, D., & Cheng, J. (2004). Potential role of body surface ECG mapping for localization of atrial fibrillation trigger sites. Journal of Electrocardiology, 37, 47-52. doi:10.1016/j.jelectrocard.2004.08.017Sippensgroenewegen, A., Roithinger, F. X., Peeters, H. A. ., Linnenbank, A. C., van Hemel, N. M., Steiner, P. R., & Lesh, M. D. (1998). Body surface mapping of atrial arrhythmias: Atlas of paced p wave integral maps to localize the focal origin of right atrial tachycardia. Journal of Electrocardiology, 31, 85-91. doi:10.1016/s0022-0736(98)90298-9SPACH, M. S., & BOINEAU, J. P. (1997). Microfibrosis Produces Electrical Load Variations Due to Loss of Side-to-Side Cell Connections; A Major Mechanism of Structural Heart Disease Arrhythmias. Pacing and Clinical Electrophysiology, 20(2), 397-413. doi:10.1111/j.1540-8159.1997.tb06199.xTrayanova, N. A., & Boyle, P. M. (2013). Advances in modeling ventricular arrhythmias: from mechanisms to the clinic. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 6(2), 209-224. doi:10.1002/wsbm.1256Vigmond, E., Pashaei, A., Amraoui, S., Cochet, H., & Hassaguerre, M. (2016). Percolation as a mechanism to explain atrial fractionated electrograms and reentry in a fibrosis model based on imaging data. Heart Rhythm, 13(7), 1536-1543. doi:10.1016/j.hrthm.2016.03.019Ward, J. H. (1963). Hierarchical Grouping to Optimize an Objective Function. Journal of the American Statistical Association, 58(301), 236-244. doi:10.1080/01621459.1963.10500845Weber, F. M., Keller, D. U. J., Bauer, S., Seemann, G., Lorenz, C., & Dössel, O. (2011). Predicting Tissue Conductivity Influences on Body Surface Potentials—An Efficient Approach Based on Principal Component Analysis. IEEE Transactions on Biomedical Engineering, 58(2), 265-273. doi:10.1109/tbme.2010.2090151Zhao, J., Kharche, S., Hansen, B., Csepe, T., Wang, Y., Stiles, M., & Fedorov, V. (2015). Optimization of Catheter Ablation of Atrial Fibrillation: Insights Gained from Clinically-Derived Computer Models. International Journal of Molecular Sciences, 16(12), 10834-10854. doi:10.3390/ijms16051083

A 2 × 2 factorial, randomised, open-label trial to determine the clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care over 52 weeks in adults with bronchiectasis:a protocol for the CLEAR clinical trial

Background: Current guidelines for the management of bronchiectasis (BE) highlight the lack of evidence to recommend mucoactive agents, such as hypertonic saline (HTS) and carbocisteine, to aid sputum removal as part of standard care. We hypothesise that mucoactive agents (HTS or carbocisteine, or a combination) are effective in reducing exacerbations over a 52-week period, compared to usual care. Methods: This is a 52-week, 2 × 2 factorial, randomized, open-label trial to determine the clinical effectiveness and cost effectiveness of HTS 6% and carbocisteine for airway clearance versus usual care-the Clinical and cost-effectiveness of hypertonic saline (HTS 6%) and carbocisteine for airway clearance versus usual care (CLEAR) trial. Patients will be randomised to (1) standard care and twice-daily nebulised HTS (6%), (2) standard care and carbocisteine (750 mg three times per day until visit 3, reducing to 750 mg twice per day), (3) standard care and combination of twice-daily nebulised HTS and carbocisteine, or (4) standard care. The primary outcome is the mean number of exacerbations over 52 weeks. Key inclusion criteria are as follows: Adults with a diagnosis of BE on computed tomography, BE as the primary respiratory diagnosis, and two or more pulmonary exacerbations in the last year requiring antibiotics and production of daily sputum. Discussion: This trial's pragmatic research design avoids the significant costs associated with double-blind trials whilst optimising rigour in other areas of trial delivery. The CLEAR trial will provide evidence as to whether HTS, carbocisteine or both are effective and cost effective for patients with BE. Trial registration: EudraCT number: 2017-000664-14 (first entered in the database on 20 October 2017). ISRCTN.com, ISRCTN89040295. Registered on 6 July/2018. Funder: National Institute for Health Research, Health Technology Assessment Programme (15/100/01). Sponsor: Belfast Health and Social Care Trust. Ethics Reference Number: 17/NE/0339. Protocol version: V3.0 Final_14052018

Standardised practices in the networked management of congenital hyperinsulinism: a UK national collaborative consensus

Congenital hyperinsulinism (CHI) is a condition characterised by severe and recurrent hypoglycaemia in infants and young children caused by inappropriate insulin over-secretion. CHI is of heterogeneous aetiology with a significant genetic component and is often unresponsive to standard medical therapy options. The treatment of CHI can be multifaceted and complex, requiring multidisciplinary input. It is important to manage hypoglycaemia in CHI promptly as the risk of long-term neurodisability arising from neuroglycopaenia is high. The UK CHI consensus on the practice and management of CHI was developed to optimise and harmonise clinical management of patients in centres specialising in CHI as well as in non-specialist centres engaged in collaborative, networked models of care. Using current best practice and a consensus approach, it provides guidance and practical advice in the domains of diagnosis, clinical assessment and treatment to mitigate hypoglycaemia risk and improve long term outcomes for health and well-being

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST): a structured study protocol for an open-label dose-escalation phase 1 trial followed by a randomised, triple-blind, allocation concealed, placebo-controlled phase 2 trial

BACKGROUND Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. This trial investigates a novel CD362 enriched umbilical cord derived MSC product (REALIST ORBCEL-C), produced to Good Manufacturing Practice standards, in patients with moderate to severe ARDS due to COVID-19 and ARDS due to other causes. METHODS Phase 1 is a multicentre open-label dose-escalation pilot trial. Patients will receive a single infusion of REALIST ORBCEL-C (100 × 10 cells, 200 × 10 cells or 400 × 10 cells) in a 3 + 3 design. Phase 2 is a multicentre randomised, triple blind, allocation concealed placebo-controlled trial. Two cohorts of patients, with ARDS due to COVID-19 or ARDS due to other causes, will be recruited and randomised 1:1 to receive either a single infusion of REALIST ORBCEL-C (400 × 10 cells or maximal tolerated dose in phase 1) or placebo. Planned recruitment to each cohort is 60 patients. The primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is oxygenation index at day 7. The trial will be reported according to the Consolidated Standards for Reporting Trials (CONSORT 2010) statement. DISCUSSION The development and manufacture of an advanced therapy medicinal product to Good Manufacturing Practice standards within NHS infrastructure are discussed, including challenges encountered during the early stages of trial set up. The rationale to include a separate cohort of patients with ARDS due to COVID-19 in phase 2 of the trial is outlined. TRIAL REGISTRATION ClinicalTrials.gov NCT03042143. Registered on 3 February 2017. EudraCT Number 2017-000584-33